This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu Y, Gray NS . Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358–364.
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S et al. Crystal structure of the T315I mutant of the Abl kinase. Chem Biol Drug Des 2007; 70: 171–181.
Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Taebo S et al. Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases. Blood 2010 (Epub ahead of print).
Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006; 2: 95–102.
Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE et al. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501–506.
Acknowledgements
JDG was supported by NIH Grant CA66996, and a Specialized Center of Research Award from the Leukemia and Lymphoma Society. JDG was also supported by NIH Grants CA36167 and DK50654.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
JDG, NG and ALK have a financial interest with Novartis Pharma AG.
Rights and permissions
About this article
Cite this article
Weisberg, E., Deng, X., Choi, H. et al. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24, 1375–1378 (2010). https://doi.org/10.1038/leu.2010.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.107
This article is cited by
-
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro
Acta Pharmacologica Sinica (2014)
-
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Nature Reviews Cancer (2012)
-
Targeting IAP proteins for therapeutic intervention in cancer
Nature Reviews Drug Discovery (2012)